Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 693 publications
SWI/SNF Alterations Define a Chromatin-Dependent Subtype of Urothelial Carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026
Host-controlled switching between TADF and RTP in acridone-carboline donor-acceptor dyads.
Journal: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Published: July 10, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.
Journal: JCO precision oncology
Published: July 08, 2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer.
Journal: JAMA network open
Published: June 29, 2026
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer.
Journal: JAMA network open
Published: June 24, 2026
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 15, 2026
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.
Journal: Circulation
Published: June 15, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.
Journal: Future oncology (London, England)
Published: June 09, 2026
[177Lu]Lu-PSMA-617 in metastatic androgen pathway modulator-sensitive prostate cancer.
Journal: Lancet (London, England)
Published: June 05, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.
Journal: Future oncology (London, England)
Published: June 04, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.
Journal: The New England journal of medicine
Published: June 01, 2026
Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular Risk.
Journal: JCO oncology practice
Published: May 29, 2026
Last Updated: 09/26/2026